Affiliation:
1. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. murphym@mskcc.org
Abstract
Voriconazole, a new azole antifungal agent, showed potent activity against clinical isolates of Aspergillus spp. in vitro. For A. fumigatus, the MIC range was < 0.03 to 0.5 microgram/ml and the MIC at which 90% of isolates are inhibited was 0.25 microgram/ml. In an experimental model of invasive pulmonary aspergillosis which mimics infection in humans, oral voriconazole at dosages of 30 mg/kg of body weight per day significantly delayed or prevented mortality.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference24 articles.
1. Barchiesi F. M. Restrepo D. A. McGough and M. G. Rinaldi. 1995. In vitro activity of a new antifungal triazole: UK-109 496 abstr. F71 p. 125. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.
2. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species;Barry A. L.;Antimicrob Agents Chemother.,1996
3. Use of a new bioassay to study pentamidine pharmacokinetics;Bernard E. M.;J. Infect. Dis.,1985
4. Fungal infections in cancer patients: an international autopsy survey;Bodey G.;Eur. J. Clin. Microbiol. Infect. Dis.,1992
5. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases;Denning D. W.;Rev. Infect. Dis.,1990
Cited by
141 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献